Idenix Pharmaceuticals, Inc. (IDIX) Reports Q3 Loss of 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Price: $24.50 --0%
Financial Fact:
Collaboration revenue - related party: -26.07M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Collaboration revenue - related party: -26.07M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) reported Q3 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $2.64 million versus the consensus estimate of $2.56 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kosmos Energy (KOS) Misses Q3 EPS by 3c
- Federal Realty Inv. Trust (FRT) Tops Q3 EPS by 3c ; Offers Guidance
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
